Literature DB >> 19854295

The quest for biomarkers in tuberculosis.

Shreemanta K Parida1, Stefan H E Kaufmann.   

Abstract

No new vaccine has been licensed for tuberculosis (TB) for more than three-quarters of a century, and no new drug has been licensed for half a century. One major drawback has been the attrition caused by the lack of a reliable biological indicator (biomarker) to predict toxicity and efficacy early in the development pipeline. This review portrays the landscape of biomarker discovery for TB in the context of drug and vaccine development using emerging global biomics platforms. The time is ripe to move from single markers for correlates of protection to a biosignature comprising a well-defined set of robust indicators in TB that can accelerate rapid screening and early selection of potential drug and vaccine candidates. Copyright (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19854295     DOI： 10.1016/j.drudis.2009.10.005

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  35 in total

1.  True facets of TB diagnosis in 2012: Hypes and realities.

Authors:  S K Parida
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-12-11

Review 2.  Towards a point-of-care test for active tuberculosis: obstacles and opportunities.

Authors:  Ruth McNerney; Peter Daley
Journal:  Nat Rev Microbiol       Date:  2011-03       Impact factor: 60.633

Review 3.  Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

Authors:  Howard Takiff; Elba Guerrero
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

Review 4.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

5.  Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.

Authors:  Carlos R Zárate-Bladés; Rodrigo F Rodrigues; Patricia R M Souza; Wendy M Rios; Luana S Soares; Rogério S Rosada; Izaíra T Brandão; Ana Paula Masson; Elaine M Floriano; Simone G Ramos; Celio L Silva
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

6.  Duration of immunity against Mycobacterium bovis following neonatal vaccination with bacillus Calmette-Guérin Danish: significant protection against infection at 12, but not 24, months.

Authors:  M L Thom; M McAulay; H M Vordermeier; D Clifford; R G Hewinson; B Villarreal-Ramos; J C Hope
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

7.  Discrimination between active and latent tuberculosis based on ratio of antigen-specific to mitogen-induced IP-10 production.

Authors:  Yun Hee Jeong; Yun-Gyoung Hur; Hyejon Lee; Sunghyun Kim; Jang-Eun Cho; Jun Chang; Sung Jae Shin; Hyeyoung Lee; Young Ae Kang; Sang-Nae Cho; Sang-Jun Ha
Journal:  J Clin Microbiol       Date:  2014-11-26       Impact factor: 5.948

8.  Quantitative Imaging Network: Data Sharing and Competitive AlgorithmValidation Leveraging The Cancer Imaging Archive.

Authors:  Jayashree Kalpathy-Cramer; John Blake Freymann; Justin Stephen Kirby; Paul Eugene Kinahan; Fred William Prior
Journal:  Transl Oncol       Date:  2014-02-01       Impact factor: 4.243

9.  Diagnostic value of blood gene expression signatures in active tuberculosis in Thais: a pilot study.

Authors:  N Satproedprai; N Wichukchinda; S Suphankong; W Inunchot; T Kuntima; S Kumpeerasart; S Wattanapokayakit; S Nedsuwan; H Yanai; K Higuchi; N Harada; S Mahasirimongkol
Journal:  Genes Immun       Date:  2015-03-12       Impact factor: 2.676

10.  Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort.

Authors:  Jayne S Sutherland; Bouke C de Jong; David J Jeffries; Ifedayo M Adetifa; Martin O C Ota
Journal:  PLoS One       Date:  2010-08-24       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.